Development of angiogenesis inhibitors to vascular endothelial growth factor receptor 2. current status and future perspective

10.2741/1629 ◽  
2005 ◽  
Vol 10 (1-3) ◽  
pp. 1415 ◽  
Author(s):  
Keren, Paz
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Growth Factor Receptor ◽  
Angiogenesis Inhibitors ◽  
Current Status ◽  
Future Perspective ◽  
Vascular Endothelial ◽  
Endothelial Growth Factor

Vandetanib (ZD6474), a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor (VEGFR) and Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinases: Current Status and Future Directions

2009 ◽  
Vol 14 (4) ◽  
pp. 378-390 ◽  
Author(s):  
Alessandro Morabito ◽  
Maria Carmela Piccirillo ◽  
Fabiano Falasconi ◽  
Gianfranco De Feo ◽  
Antonia Del Giudice ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Tyrosine Kinases ◽  
Growth Factor Receptor ◽  
Current Status ◽  
Vascular Endothelial ◽  
Dual Inhibitor ◽  
Future Directions ◽  
Epidermal Growth ◽  
Endothelial Growth Factor

Systemic therapy for relapsed/refractory meningioma: Is there potential for antiangiogenic agents?

2018 ◽  
Vol 25 (3) ◽  
pp. 638-647 ◽  
Author(s):  
Constantin A Dasanu ◽  
Yazeed Samara ◽  
Ion Codreanu ◽  
Farhad M Limonadi ◽  
Omid Hamid ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Systemic Therapy ◽  
Antiangiogenic Therapy ◽  
Growth Factor Receptor ◽  
Current Status ◽  
Antiangiogenic Agents ◽  
Vascular Endothelial ◽  
Phase Ii Trials ◽  
Endothelial Growth Factor

Effective therapies for relapsed/refractory meningioma after surgery and radiation therapy represent an unmet need. Most meningiomas are highly vascularized tumors and, therefore, potentially amenable to antiangiogenic therapy. Herein, we review comprehensively the scientific literature on systemic therapy options for relapsed, persistent or metastatic meningioma, not amenable to local therapy. Also, this review offers insights into the function of vascular endothelial growth factor/receptor pathway both in health and disease. Further, we address the current status of the preclinical and clinical studies targeting vascular endothelial growth factor/receptor signaling in meningioma. Most relevant publications were identified through searching the PubMed/Medline database for articles published from inception to 1 February 2018. Vascular endothelial growth factor pathway activation might represent the primary driver of angiogenesis in meningioma. Positive findings of two prospective phase II trials, supported by the results of several retrospective cohorts, suggest a clinical benefit for the vascular endothelial growth factor inhibitor bevacizumab in refractory meningioma. Bevacizumab causes both peritumoral brain edema reduction and true meningioma shrinkage. Patients with WHO grades II–III meningioma appear to benefit more than patients with grade I disease. Similarly, responses have been documented with certain oral targeted anti-vascular endothelial growth factor/receptor agents. Further exploration of the role of vascular endothelial growth factor/receptor inhibitors in refractory meningioma seems warranted.

Fortgeschrittenes medulläres Schilddrüsenkarzinom: Vandetanib verbessert das progressionsfreie Überleben

2012 ◽  
Vol 03 (02) ◽  
pp. 93-92
Author(s):  
Alexander Kretzschmar
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Growth Factor Receptor ◽  
Phase Iii ◽  
Vascular Endothelial ◽  
Medulläres Schilddrüsenkarzinom ◽  
Epidermal Growth ◽  
Endothelial Growth Factor

Vandetanib ist ein oraler Hemmer des RET-Kinase-, VEGF (Vascular Endothelial Growth Factor Receptor)- und EGFR (Epidermal Growth Factor Receptor)-Signalwegs. In einer zulassungsrelevanten, randomisierten, doppelblinden, placebokontrollierten Phase- III-Studie verlängerte der Tyrosinkinasehemmer das progressionsfreie Überleben (PFS) signifikant länger als Placebo.

Sign in / Sign up

Export Citation Format

Share Document